Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Riboflavin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.96 |
| ▸ | USP2 | O75604 | 4/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.96 |
| ▸ | HAT1 | O14929 | 4/20 | 0.96 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.96 |
| ▸ | HTT | P42858 | 4/20 | 0.96 |
| ▸ | RECQL | P46063 | 3/20 | 0.96 |
| ▸ | CASP7 | P55210 | 3/20 | 0.96 |
| ▸ | MAPT | P10636 | 3/20 | 0.96 |
| ▸ | CASP1 | P29466 | 2/20 | 0.96 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.96 |
| ▸ | TST | Q16762 | 2/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | HBB | P68871 | 1/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riboflavin SCHEMBL15121522 | 1.00 | MEN1 (0.96) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL14146654 | 0.98 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL5899262 | 0.98 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL29456492 | 0.98 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL2420598 | 0.98 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL13373926 | 0.98 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL7706 | 0.98 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL9609755 | 0.98 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL12979917 | 0.98 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL7707 | 0.98 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785503-B2 | Biphenyl compound or pharmaceutically acceptable salt thereof, method for preparing novel biphenyl compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient for preventing or treating diabetes complications | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2014-07-22 | — | — | US | disclosed |
| US-20130210928-A1 | NOVEL BIPHENYL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PREPARING NOVEL BIPHENYL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING DIABETES COMPLICATIONS | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2013-08-15 | — | — | US | disclosed |
| EP-2617702-A2 | NOVEL BIPHENYL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PREPARING NOVEL BIPHENYL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING DIABETES COMPLICATIONS | Korea Institute of Oriental Medicine (KR) | 2013-07-24 | — | — | EP | disclosed |
| CN-101277712-A | The composition comprising extract of cinnamomum cassia bark for improving normal flora and enhancing immune response | KOREA INST ORIENTAL MEDICINE (KR) | 2008-10-01 | — | — | CN | disclosed |
| WO-2007007958-A1 | HERBAL PHARMACEUTICAL COMPOSITION FOR REGENERATIVE AGENT OF CARTILAGINOUS TISSUE AND TREATMENT OF OSTEOARTHRITIS | YUHAN CORPORATION (KR) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210928-A1 | NOVEL BIPHENYL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PREPARING NOVEL BIPHENYL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING DIABETES COMPLICATIONS | VEGFA, KDR, SMO | MEN1 4593/4885KMT2A 2443/4885USP2 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.